Peritoneal Tumors and Metastases (PDF)

(CAES), past chair of the German Association for the Study of the Liver, past chair of the Austrian society of transplantation, past board member of the European Liver and Intestine Transplantation Association (ELITA), and a Fellow of the American College of Surgery (FACS). With more than 500 publications in scientific journals to his credit, his main focus is on surgical oncology, especially HBP surgery and cytoreductive surgery, HIPEC, PIPAC, and organ transplantation.




Faheez Mohamed graduated from the University of Edinburgh and underwent surgical training in the North East of England with a period of research at the Washington Cancer Institute, USA under the supervision of Dr Paul Sugarbaker. He was appointed Consultant Surgeon at the Peritoneal Malignancy Institute, Basingstoke in 2009 with an interest in cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the treatment of peritoneal malignancy. He is currently Clinical Director of the Department of General Surgery at Hampshire Hospitals Foundation Trust and is the Clinical Lead for the UK Colorectal Peritoneal Malignancy Clinical Database. He is actively involved in clinical and basic science research in the field of peritoneal malignancy.

Paul Sugarbaker is a graduate of Cornell University Medical College in New York City. His surgical training was at the Peter Bent Brigham Hospital in Boston, Massachusetts. Immediately following his residency training he completed a Masters Degree in Tumor Immunology from Harvard University. From Boston he went to Bethesda, Maryland and spent a decade at the Surgery Branch, National Cancer Institute, National Institutes of Health (NIH). His focus at the NIH was sarcoma surgery, colorectal and liver metastases, and peritoneal metastases. After a brief 3 year stay at the Emory Clinic in Atlanta, Georgia, he returned to Washington, DC to establish the Program in Peritoneal Surface Malignancy at the Washington Cancer Institute. For 31 years he has been involved in pharmacologic and clinical research in patients with peritoneal metastases. His efforts and the efforts of the fellows in the program have resulted in over a thousand published manuscripts. Currently, he is involved in surgical problem solving in an effort to optimize the management of peritoneal metastases from both gynecologic and gastrointestinal malignancy. He is currently the Secretary General for the Peritoneal Surface Oncology Group International (PSOGI).